Graham Hind, Chief Executive of BioProgress, said: "As part of the ongoing
process of developing the TABWRAP technology , we have provided several
different developing working prototypes to customers and have received extremely
positive feedback,.
blotters(TM), m-doc(TM), SEAL-ON(TM) are all trademarks of Alltracel
Pharmaceuticals PLC.

carrageenan guar

The TABWRAP machine is planned to be demonstrable by September 2005 in time
for a commercial launch in November at the CPhl Worldwide and the International
Control Services Expo exhibitions in Madrid. Detailed information about factors pertinent to the
business of the company that could cause actual results to differ is set forth
in the Company's filings with the Securities and Exchange Commission.com

UK Media enquiries:

Abchurch

Henry Harrison -Topham / Heather Salmond Tel: +44 (0) 20 7398 7700
www.

The Company's business model provides it with several significant revenue
streams including sales of encapsulating machines and film, plus licence and
fees for research development services.

- Comparative analysis with statins in this study have also shown that
m. As well as both reducing LDL cholesterol and
improving the HDL/LDL ratio these studies have now revealed significant
longer term coronary health benefits of m.
- In the Cholesterol Management market, pre-clinical studies have
demonstrated the m-doc(TM) technology platform success in reducing
cholesterol and improving the hdl/ldl ratio ** and a patient efficacy study is
currently underway. Routes to market are under
commercial consideration .g.

xanthan stabilisers

We are particularly pleased that these result show significant
indications that the m. Alltracel 's specialist oral care division Westone was acquired in
January 2005 and is headquartered in London , UK with manufacturing facilities
in Shenzhen, China.

colloids stabilizing

All these solutions involve expensive batch
based technologies which we believe are unsustainable in the long term in an
environment where governments are closely reviewing the cost of pharmaceutical
drugs and asking searching questions about the efficiency of the pharmaceutical
manufacturing process."

- Ends -

Forward looking Information.doc(TM) could also be used in
an additive combination with sterols as they have a dissimilar
mode of action that displaces cholesterol from mixed micelles and
therefore affects cholesterol transport to the bloodstream.com) Alltracel Pharmaceuticals Plc
is a brand focused, market driven, bio-pharmaceutical R+D company
specialising in polysaccharides manipulation and PTFE technologies for the
medical device, oral care and food ingredient markets.
m-doc(TM) (Micro Dispersed Oxidized Cellulose; (http://www.

stabilizing husk

The ability to manipulate the
dissolution rates of the tablet wrapping film formulations enables BioProgress
to design-in advanced rapid active release characteristics that are particularly
important for analgesics. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances.L), the brand focused,
bio-pharmaceutical R+D company specialising in the medical device, oral care
and food ingredient markets, is pleased to report on the successful
completion of the fifteen month long program of animal trials and other
pre-clinical research on the cholesterol reduction efficacy of Alltracel's
m-doc(TM) technology platform.

- The method of action is centred on m.

carrageenan sucrose

This announcement contains certain "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995., (AIM: AP.
blotters(TM) is Alltracel's branded blood stopping thin film technology
for the consumer first aid market.

pectin tapioca

The first commercial TABWRAP machines will have a design output of 120,000
tablets per hour but the design incorporates the potential to double this output
and even greater outputs are feasible, enabling the technology to be coupled to
some of the world's fastest tablet presses.

The TABWRAP process is revolutionary and incorporates state of the art
technology in fast tablet processing, innovative film cutting and a unique
overlap film tamper-evident sealing process. The consumer wants a
coated easy-to-swallow tablet but this currently means either a gelatin , sugar
or cellulose spray coated tablet. The forward-looking statements in this release include statements
addressing future financial and operating results and the timing and benefits of
the reorganisation.

The Company has also developed patented and licensed the world's first flushable
ostomy pouch that offers a newly enhanced quality of life not previously
possible for the end user.doc(TM) reduced LDL* cholesterol levels and improved the
HDL/LDL** ratio. Importantly , m.

- In addition it is suggested that m.

gums hydrocolloid

Press Release 3 March 2005

BioProgress plc

("BioProgress" or "the Company")

BioProgress places GBP1.co.

"The interest in this technology is now rapidly growing. Specifically:

- Statins target and inhibit an enzyme (HMGCo-A reductase) that is
necessary for the production of cholesterol in the liver thereby
reducing serum cholesterol levels.doc(TM) has been
classified as a (non drug) by both the Irish and Czech (Medicine
Boards) for this cholesterol lowering action. Headquartered in
Dublin, Ireland and with an R+D subsidiary in the Czech Republic , Alltracel
was founded in 1996 and listed on London's Alternative Investment Market in
July 2001 .com )) is the
end product of Alltracel's patented process and is currently targeting two
major markets. shaving nicks
m-doc is released on contact with the blood, forming a soft gel-like layer
over the wound to stop the bleeding fast.

microcrystalline husk

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. Persons
into whose possession this announcement comes are required to inform themselves
about and to observe such restrictions.

This information is provided by RNS
The company news service from the London Stock Exchange

V-CAM is
intimately linked to the development of atherosclerotic plaque
and therefore its reduction by m.doc(TM) is directly decreasing
the chance of atherosclerosis significantly.

- These findings suggest that commercial routes to market will be
available for m.doc(TM) specifically in the area of
arterial plaque build -up prevention.
Alltracel (AIM: AP.

stabilizing thickening

Tony Richardson, Chief Executive Officer, Alltracel Pharmaceuticals Plc,
commented:
"The completion of our pre-clinical studies is a real breakthrough in
understanding the mechanism of action and significant coronary health
benefits that m.

stabilizers agar

The distribution of the announcement and/or
issue of securities in certain jurisdictions may be restricted by law.

stabilizing perkasa

This follows an extensive internal design programme within BioProgress
and the production and testing of several prototype TABWRAP machines.

The decision to award the order to Innomech was taken in full consultation with
Harro Hoefliger which is currently heavily committed to other projects with
BioProgress and other customers. Innomech will build the first machine,
but Harro Hoefliger will optimize the production machine design and then it is
intended that they will build batches of commercial TABWRAP machines,
supplying, commissioning and providing the necessary global after sales service. The
Company is under no obligation to (and expressly disclaim any such obligation
to) update or alter its forward-looking statements whether as a result of new
information, future events or otherwise.

- The compelling conclusion is that m."
**LDL: Low Density Lipoproteins
*HLD/LDL Ratio: Ratio of High Density Lipoproteins to Low Density
Lipoproteins: This ratio is an indicator of the extent to which blood
transports cholesterol and lipids.
- In the Wound Care market this process applied to cotton in the form of
raw cellulose is proven as an effective and efficient haemostatic
(blood-stopping) agent.

gum psyllium

BioProgress has
an excellent relationship with Perrigo and discussions are now underway as to
how best to give Perrigo access to the UK designed technology as early as
possible.

"Technologies like TABWRAP, which are fast and continuous eliminating slow
batch-based systems, can change the economics of the traditional tablet
production process but also offer major new innovation opportunities for the
pharmaceutical product marketeers.L) (http://www.

colloids pectin

20,000 pharmaceutical decision
makers from 110 countries are expected to attend.bioprogress.com

Notes to editors:

BioProgress listed on AIM in May 2003 and on NASDAQ in October 2004, and is
engaged in the research, development, and design of patented encapsulation
systems that use water soluble and biodegradable films for the dietary
supplement, pharmaceutical and other sectors.doc(TM) cholesterol lowering effect would
be additive, thereby enabling the statin dosage to be lowered
whilst maintaining efficacy .

guar sucrose

The Company's portfolio comprises
over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies.

Market research shows the global ostomy market to be
worth $1 billion annually.doc(TM) reduces serum
cholesterol levels by a distinct mechanism that involves
influencing cholesterol absorption in the intestine.
SEAL-ON(TM) (http://www.seal-on.

pectin algas

innomech.

For further information:

BioProgress plc

Graham Hind, Chief Executive Tel: +44 (0 ) 1354 655674
www. BioProgress aims to provide a cost effective and animal-free
encapsulation process for pharmaceutical drugs in liquids, tablets and powders,
thereby addressing the needs of the entire market for oral dosage forms while
providing novel delivery mechanisms not possible with traditional processes. m.com ) is the world's first first-aid treatment
brand featuring stops bleeding m-doc(TM) as standard.

gums psyllium

5 million order to build the first commercial TABWRAP machine

BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the provider of innovative delivery
mechanisms for the pharmaceutical oral dosage markets, announces that it has
placed a GBP1.5 million order with Innomech Automation Solutions in Cambridgeshire
UK (www.

Innomech are very experienced in building complex machines to high specification
pharmaceutical standards and meeting both European and FDA approval
requirements .doc(TM) offers.doc(TM) coronary health benefits are additive in
nature, to both statins and sterols , and as such our future trial and product
development work will progress down both the nutraceutical and pharmaceutical
routes to market with suitable development partners.

husk sucrose

In addition, further details on the current
human trials being undertaken for patient safety and efficacy will be
announced before April 15th 2005.doc(TM) exhibits a different and complimentary method of action to
statins .doc(TM) could be used in
combination with statins for treatment at the early stages of
atherosclerosis; the m. As a result, exploratory discussions
with potential partners have been initiated. In addition m-doc(TM) is the active ingredient in the Alltracel
owned consumer brand range SEAL-ON(TM). The blotters(TM) are small, thin, film
strips (similar to breath freshener strips) impregnated with m-doc(TM) -
Alltracel's unique blood stopping ingredient and are packed in a convenient
pocket-sized plastic dispenser.

perkasa stabilisers

com

US Investor enquiries:

Taylor Rafferty

Andrew Saunders Tel: +1 212 889 4350
www.
In summary
The recently completed animal studies; which took place in the EU
indicate the following:

- In a previous statement, Alltracel announced findings that
showed m.doc(TM) significantly
reducing the expression of V-CAM1 in blood vessels.

xanthan husk

doc(TM) Demonstrates a Lipid Dependent and Non Systemic Mode of
Action Indicating Likely Additive Cholesterol Profile Benefits Specifically
in Combination with Certain Statins and Sterols
- Commercial Partnership Discussions Initiating with Development Partners
in Both Pharmaceutical and Nutraceutical Sectors

Alltracel Pharmaceuticals Plc. Today's announcement highlights findings that
indicates that m. This results
in an overall lowering of LDL (bad) cholesterol in the
bloodstream. The SEAL-ON(TM ) range
features seven different product delivery systems - sprays, nasal plugs,
patches, powder , plasters, dressings and blotters(TM) -- each designed for
specific usage occasions and all containing the stops-bleeding m-doc(TM)
ingredient brand.

agar sucrose

PRESS RELEASE BioProgress PLC announces Placed Order

Under the Company's licensing agreement with Perrigo that was outlined in an
announcement on 8 March 2004, Perrigo acquired an exclusive license for TABWRAP in a specific market sector within North America and the EU. Actual results may
vary materially from the expectations contained in the forward-looking
statements.

Completed Alltracel Pre-Clinical Studies Indicate Significant Longer Term Coronary Health Benefits of the m.doc(TM) Technology Platform and an Additive Method

doc(TM) May Decrease the Chance of Atherosclerosis by Preventing
Build up of the Artery Clogging Plaque
- m.doc(TM) also works particularly well in preventing
the build up of artery clogging plaque , and thereby reduces the chance
of atherosclerosis which is a significant cause of cardiovascular
disease.doc(TM) based products through both the Nutraceutical
+ Pharmaceutical industries .m-doc. Patents have been granted for cholesterol management
applications in the USA, Australia and the EU.

thickener tragacanth

sucrose stabilizing

uk) to build the first full size commercial
TABWRAP machine. As a result, Harro Hoefliger could not commit
to meeting the required timeframe for delivery of the first full sized
demonstrable fully automated TABWRAP machine and enable the demonstration of
the TABWRAP technology at the commercial launch which is targeted for November
2005. They specialise in the cross fertilisation of technologies , high
accuracy pick & place systems, machine vision and precision measurement, control
systems , lasers and advanced robotics. This announcement is for information
only and does not constitute an offer or invitation to acquire or dispose of any
securities or investment advice. When placed on minor cuts e.

hydrocolloid microcrystalline

It is then intended that the
TABWRAP machine will be fully commissioned, operational and ready to install
into one of a number of interested contract pharmaceutical manufacturers during
the first quarter of 2006. This will enable product development and production
to be carried out for customers who have ordered TABWRAP machines or the
contract manufacture of TABWRAP products for those who wish to adopt the
technology but do not initially wish to order their own machines .abchurch-group. Here m-doc(TM) is currently being marketed as the
leading stops bleeding ingredient brand within recognized wound care brands
worldwide.

guar stabilizers

taylor-rafferty. DUBLIN, Ireland and PRAGUE , Czech Republic,
- m.alltracel.